UPF
11.5.2021 07:02:09 CEST | Business Wire | Press release
World leaders and experts joined more than a million global participants for the launch of “Think Tank 2022” on May 9 KST during the virtual 6th Rally of Hope for the peaceful reunification of the Korean Peninsula.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210510006060/en/
The rally, sponsored by the Universal Peace Federation (UPF), was streamed live from South Korea to 194 nations and translated into 14 languages. Think Tank 2022 is a global multi-sector network of more than 2,000 experts from a wide range of fields—government, business, academia, faith, media, arts and culture—dedicated to the collaborative search for solutions to the world’s most critical challenges.
World-class leaders including the rally’s 12 keynote speakers affirmed and enhanced the concept of Think Tank 2022. “This network will make a difference for peace on the Korean Peninsula through international unity,” said Ban Ki-Moon , former United Nations Secretary-General and chairman of the new initiative. “I applaud Dr. Hak Ja Han Moon, UPF, and the leaders of Think Tank 2022.”
Former European Commission President José Manuel Barroso reminded the audience, that “peace also includes goodwill, trust and justice. The foundation of peace is each human being. The coronavirus taught us the lesson that we have to act and cooperate on a global scale.” “As leaders from around the world who cherish the values of faith, family, democracy and justice under law,” said former U.S. Vice President Mike Pence . “I commend you for coming together at this event to continue to sow the seeds of peace, believing that in time we will reap a harvest of peace that will benefit the people of Korea, the United States and all mankind.”
Born in present-day North Korea, UPF co-founders Dr. Hak Ja Han Moon and her late husband, Rev. Dr. Sun Myung Moon, fled to the south during the Korean War and have devoted their lives to advancing a more peaceful world and reuniting Korea. Think Tank 2022, will spearhead peacebuilding initiatives such as a UN Peace Park on the DMZ; building a Korea-Japan undersea tunnel; boosting Geumgang Mountain tourism development; and helping separated Korean families find their relatives.
“A reunified, denuclearized Korean Peninsula will bring massive peace and prosperity to the peninsula and to the region,” said Mike Pompeo , former U.S. Secretary of State and CIA Director. “Religious freedom is indeed the foundation of all freedoms...with prayer, faith, and commitment to the Lord, peace will follow.”
Many speakers, including former Republic of Korea Prime Minister Chung Sye-Kyun and Cambodian Prime Minister Hun Sen , praised the timeliness of Think Tank 2022 where “international cooperation and solidarity is needed now more than ever,” said Chung.
From Africa, Zanzibar President Dr. Hussein Ali Mwinyi recalled that Africans took part in the Korean War and long for peace and democracy in that region. The peaceful reunification of Korea will lead to “explosive growth,” said renowned American businessman and investor Mr. Jim Rogers . “If trains run through the DMZ and cars run on highways, there will be endless economic development opportunities...benefiting not only the two Koreas, but also China, Russia, Japan and Asia and the whole world.”
Mr. David Beasely , executive director of the United Nations World Food Programme, the world’s largest humanitarian organization and 2020 recipient of the Nobel Peace Prize, said, “This rally is reaching across continents, uniting people all over the world in a spirit of peace, mutual prosperity and public service.”
Governments have failed because they couldn’t go beyond “their bureaucracies, their biases, and their fears,” said Newt Gingrich , former U.S. Speaker of the House of Representatives. Think Tank 2022 offers a new way for people from multiple nations to work together “outside the traditional, formal structures” he said.
“Times of crisis often tend to be the moments of greatest opportunity,” said Mark Esper , former U.S. Secretary of Defense.
"Prof. Sarah Gilbert , co-developer of the Oxford/Astra-Zeneca vaccine said that great advances would result from the challenge of the pandemic, including much speedier development of vaccines to cope with new and mutant viruses. Much greater cooperation between nations was needed to ensure the effective roll-out of the currently available vaccines to nations afflicted by the pandemic as well as greater generosity on the part of richer nations to poorer ones".
The 6th Rally of Hope, part of a digital series started by Dr. Moon in August 2020, has brought together tens of millions of people worldwide who embrace freedom, peace, and unity based on the shared ideals of interdependence, mutual prosperity, and universal values. The Washington Times article on the rally is available here .
Rally of Hope Website (video with highlights of the event): https://www.rallyofhope.eu
View source version on businesswire.com: https://www.businesswire.com/news/home/20210510006060/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
